Figure 2E shows that m6A enriched in start codons tends to have higher CVs in cancer tissues than m6A in stop codons. Moreover, we used the TP53 and HSPD1 genes as examples to study variations in m6A in cancer, and found that TP53 and HSPD1 showed higher variations in m6A at the start of CDS in colon cancer and endometrial cancer than in normal tissues (Figure 2F, Figure S3C). This evidence concerns the gene TP53 and colonic neoplasm.